Table 4.

Univariate and multivariate analyses for RSCCs and LSCRs

	Overall survival
	RSCCs				LSCRs
	Univariate		Multivariate		Univariate		Multivariate
Variable	RR (95% CI)	P	RR (95% CI)	P	RR (95% CI)	P	RR (95% CI)	P
T stage	2.284 (0.205–25.41)	0.502			0.271 (0.064–1.141)	0.075
LVI	1.219 (0.449–3.306)	0.697			1.198 (0.794–1.807)	0.389
PNI	0.595 (0.211–2.441)	0.717			1.913 (0.806–.542)	0.142
N stage	0.911 (0.267–4.717)	0.847			0.566 (0.131–2.445)	0.446
Regional LNs	0.973 (0.913–1.036)	0.388			0.90 (.929–.013)	0.170
Metastasis LNs	1.040 (0.960–1.126)	0.336			1.04 (0.987–1.112)	0.123
Sex	1.363 (0.693–2.681)	0.369			1.143 (0.735–1.778)	0.553
Diameter of LM	1.705 (0.833–3.491)	0.144			1.75 (.153–2.656)	0.009
Neo-chemo	2.263 (0.931–5.504)	0.072			0.846 (0.424–1.686)	0.635
Histological type	2.696 (1.327–5.476)	0.006	0.313 (0.134–0.729)	0.02	0.519 (0.203–0.923)	0.001	0.346 (0.131–0.913)	0.032
CA199	0.826 (0.426–1.621)	0.578			2.087 (1.371–3.177)	0.001
Number of LM	1.864 (0.886–3.923)	0.101			2.022 (1.274–3.211)	0.003	2.183 (1.243–3.833)	0.007
CEA	1.075 (0.503–2.300)	0.852			2.310 (1.42–624)	0.001
Systemic chemo	0.620 (0.267–1.442)	0.267			0.830 (0.462–1.492)	0.533
Palliative resection	1.041 (0.500–2.179)	0.910			1.767 (11.15–2.716)	0.009	1.767 (1.150–2.716)	0.011

RSCC right-side colon cancer, LSCRC left-side colorectal cancer, RR risk ratio, CI confidence interval, LVI lymphovascular invasion, PNI perineural invasion, LNs lymph nodes, LM liver metastasis, Neo-chemo neoadjuvant chemotherapy, CEA carcinoembryonic antigen, CA cancer antigen